{"id":"W3037060742","doi":"10.1111/bjd.19341","title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":206,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"AbbVie","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Interleukin 17; Internal medicine; Randomized controlled trial; Clinical endpoint; Confidence interval; Clinical trial; Dermatology; Psoriatic arthritis; Cytokine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003713331,0.001237585,0.002552476,0.0003019938,0.0003285789,0.001139757,0.0006245233,0.001586945,0.003535782],"category_scores_gemma":[0.002716729,0.0005908656,0.002486925,0.0002918154,0.001082618,0.00099899,0.0004674076,0.002408098,0.0005279802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004293114,"about_ca_system_score_gemma":0.0006996278,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003234189,"about_ca_topic_score_gemma":0.0008584943,"domain_scores_codex":[0.9985251,0.0009587196,0.0001100157,0.0001853633,0.00009953285,0.0001213268],"domain_scores_gemma":[0.9981273,0.0007770975,0.000420779,0.0001325314,0.0001009987,0.0004413077],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9766301,0.005538354,0.0007341026,0.0003635196,0.001066049,0.00001924293,0.00005984857,0.0002407508,0.003127001,0.00005761501,0.0003557368,0.01180763],"study_design_scores_gemma":[0.8217445,0.1723814,0.003405316,0.00003845053,0.0007946377,0.00004276363,0.00002838867,0.0003516429,0.0006819082,0.00009313253,0.0004207204,0.00001710194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935361,0.003500403,0.0002863877,0.0003254747,0.0002166781,0.0008232658,0.0003872317,0.00005048198,0.0008741283],"genre_scores_gemma":[0.9953777,0.001242978,0.0006975603,0.0005261137,0.0002385783,0.0008335016,0.0004683236,0.000011556,0.0006036299],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003713331,"threshold_uncertainty_score":0.01963818,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04242110571347812,"score_gpt":0.3147352210618506,"score_spread":0.2723141153483725,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}